Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline M Tanner

Showing results (181-190 of 207) with videos related to

Pageof 21
Sort By:
Environmental Health Perspectives|August 13, 2013
Research on the premotor symptoms of Parkinson's disease: clinical and etiological implicationsHonglei Chen, Edward A Burton, G Webster Ross, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
Environmental Health Perspectives|January 24, 2009
Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007Jeff Bronstein, Paul Carvey, Honglei Chen, et al.
The Lancet. Neurology|June 21, 2017
Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohortsGanqiang Liu, Joseph J Locascio, Jean-Christophe Corvol, et al.
Frontiers in Aging Neuroscience|November 2, 2020
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)Andrea Sturchio, Luca Marsili, Joaquin A Vizcarra, et al.
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Cinpanemab in Early Parkinson's DiseaseAnthony E Lang, Andrew D Siderowf, Eric A Macklin, et al.
Journal of Parkinson'S Disease|April 5, 2024
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials InitiativeRichard K Wyse, Tom Isaacs, Roger A Barker, et al.
Parkinsonism & Related Disorders|October 23, 2016
Knowledge gaps and research recommendations for essential tremorFranziska Hopfner, Dietrich Haubenberger, Wendy R Galpern, et al.
Neurology|February 13, 2019
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseasesAlberto J Espay, Joaquin A Vizcarra, Luca Marsili, et al.
Pageof 21

Showing results (181-190 of 207) with videos related to

Sort By:
Pageof 21
Environmental Health Perspectives|August 13, 2013
Research on the premotor symptoms of Parkinson's disease: clinical and etiological implicationsHonglei Chen, Edward A Burton, G Webster Ross, et al.
Neurology|February 2, 2024
Evaluation of ATN<sub>PD</sub> Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson DiseaseKatheryn A Q Cousins, David J Irwin, Thomas F Tropea, et al.
Environmental Health Perspectives|January 24, 2009
Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007Jeff Bronstein, Paul Carvey, Honglei Chen, et al.
The Lancet. Neurology|June 21, 2017
Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohortsGanqiang Liu, Joseph J Locascio, Jean-Christophe Corvol, et al.
Frontiers in Aging Neuroscience|November 2, 2020
Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)Andrea Sturchio, Luca Marsili, Joaquin A Vizcarra, et al.
Acta Neuropathologica|March 30, 2016
CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative studyJu-Hee Kang, Brit Mollenhauer, Christopher S Coffey, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Cinpanemab in Early Parkinson's DiseaseAnthony E Lang, Andrew D Siderowf, Eric A Macklin, et al.
Journal of Parkinson'S Disease|April 5, 2024
Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials InitiativeRichard K Wyse, Tom Isaacs, Roger A Barker, et al.
Parkinsonism & Related Disorders|October 23, 2016
Knowledge gaps and research recommendations for essential tremorFranziska Hopfner, Dietrich Haubenberger, Wendy R Galpern, et al.
Neurology|February 13, 2019
Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseasesAlberto J Espay, Joaquin A Vizcarra, Luca Marsili, et al.
Pageof 21